Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403325 · ClinicalTrials.gov registry record · Phase 1
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
A Phase 1 study of Central Serous Chorioretinopathy, sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00403325 is a Phase 1 study of Central Serous Chorioretinopathy that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 9 participants, below the 88-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00403325, a Phase 1 study of Central Serous Chorioretinopathy, has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Conditions Studied
Interventions
- DRUG rhuFab V2 [ranibizumab] ( Lucentis )
Study Locations (1)
New York
- Vitreous Retina Macula Consultants of New York, P.C. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403325
The ClinicalTrials.gov registry entry for NCT00403325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (90% lower). The listed sponsor is Vitreous -Retina- Macula Consultants of New York, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 1 intervention - of which rhuFab V2 [ranibizumab] ( Lucentis ) is the first listed.
NCT00403325 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00403325 about?
NCT00403325 is a clinical study titled "Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy". The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
What is the current status of trial NCT00403325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-08.
What conditions does trial NCT00403325 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT00403325?
The interventions under investigation include: rhuFab V2 [ranibizumab] ( Lucentis ) (DRUG).
Who is sponsoring clinical trial NCT00403325?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00403325 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.